Khondrion BV

Khondrion BV
Philips van Leydenlaan 15 (west entrance)
6525 EX Nijmegen
The Netherlands

Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. The company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.

The company’s in-house discovery engine is using unique live-cell imaging technologies, patient-derived cell lines and predictive cell-based disease models to build a portfolio of promising compounds.

Active discovery programmes are underway developing new therapies, biomarkers and new read-out technologies in the field of mitochondrial diseases.

To accelerate the discovery and development of its potential medicines for mitochondrial diseases, Khondrion collaborates with a global clinical and academic network and patient organisations internationally.

Khondrion is headquartered in Nijmegen, The Netherlands.

  • Photo of Jan Smeitink
    Prof. Dr. Jan Smeitink

    Prof. Dr. Jan Smeitink is CEO and founder of Khondrion.

    With more than 25 years’ experience in patient care, diagnostics and research for patients suffering from mitochondrial disease, Jan is the Founder and CEO of Khondrion. He also holds a position as Professor in Mitochondrial Medicine at the Radboud University Medical Center (RUMC) in the Netherlands and has been appointed foreign adjunct professor at the Karolinska Institutet in Stockholm, Sweden. In addition, he coordinates the Radboud Center for Mitochondrial Medicine (RCMM) at the Radboud UMC. He has published more than 375 peer-reviewed scientific papers.

  • Photo of Julien Beyrath
    Dr. Julien Beyrath

    Dr. Julien Beyrath is Chief Operating Officer and Scientific Officer at Khondrion.

    Julien holds a PhD in molecular and cellular biology with a major in Pharmacology from the University of Strasbourg, France. Prior to working at Khondrion, Julien was a researcher at the Centre for Systems Biology and Bioenergetics of the Radboud University Medical Center, the Netherlands, focusing on the identification of new drug targets for mitochondrial disease. He has expertise in the discovery of drug candidates and their pre-clinical development. Julien is responsible for internal and external research and development programs and manages the day-to-day operations of the Khondrion laboratories.